Citigroup Upgrades Prime Medicine to Buy, Announces $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy and set a price target of $10.
May 16, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Samantha Semenkow has upgraded Prime Medicine (NASDAQ:PRME) from Neutral to Buy and set a price target of $10.
The upgrade from Neutral to Buy and the announcement of a $10 price target by a reputable analyst at Citigroup is likely to positively impact Prime Medicine's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100